Financial reports
10-Q
2024 Q2
Quarterly report
12 Aug 24
10-Q
2024 Q1
Quarterly report
9 May 24
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
27 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
Current reports
8-K
California Institute for Regenerative Medicine Awards Funding for
26 Jul 24
8-K
Changes in Registrant's Certifying Accountant
19 Jul 24
8-K
Departure of Directors or Certain Officers
14 Jun 24
8-K
Unregistered Sales of Equity Securities
20 May 24
8-K
Immix Biopharma Announces Proposed Public Offering of Common Stock
6 Feb 24
8-K
Other Events
5 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Aug 23
8-K
Entry into a Material Definitive Agreement
14 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Entry into a Material Definitive Agreement
22 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
19 Jul 24
D
Indefinite amount in equity, 14 investors
20 May 24
S-8
Registration of securities for employees
16 Feb 24
424B5
Prospectus supplement for primary offering
7 Feb 24
424B5
Prospectus supplement for primary offering
5 Feb 24
S-3
Shelf registration
25 Sep 23
424B5
Prospectus supplement for primary offering
14 Jul 23
S-8
Registration of securities for employees
13 Jun 23
424B5
Prospectus supplement for primary offering
22 Mar 23
S-3
Shelf registration
3 Jan 23
Other
EFFECT
Notice of effectiveness
29 Sep 23
CORRESP
Correspondence with SEC
26 Sep 23
UPLOAD
Letter from SEC
26 Sep 23
EFFECT
Notice of effectiveness
12 Jan 23
CORRESP
Correspondence with SEC
9 Jan 23
UPLOAD
Letter from SEC
6 Jan 23
EFFECT
Notice of effectiveness
16 Dec 21
SEC STAFF
SEC staff action: Order
15 Dec 21
CERT
Certification of approval for exchange listing
14 Dec 21
CORRESP
Correspondence with SEC
13 Dec 21